Compounded Semaglutide: A Practical Guide

Compounded semaglutide is a prescription-only GLP-1 medication made by a licensed compounding pharmacy rather than by the company that originally developed the molecule. It exists because a licensed prescriber has decided that a compounded version is appropriate for a particular patient, and a pharmacy has then prepared it to that prescription. It is not an approved medicine in the regulatory sense, and the safeguards around it are different from those around a licensed product. Understanding those differences is the whole point of this guide.

That distinction matters more in rare disease and complex care than it does in ordinary weight management. People living with a rare endocrine or metabolic condition often arrive at a clinic having already tried several treatments, and they tend to ask sharper questions than most: what exactly is in this vial, who made it, and what happens if it goes wrong. Those are the right questions. They are also the questions that a compounded product makes harder to answer, because the usual chain of regulatory assurance is shorter. This piece sets out what compounded semaglutide is, where it sits in the wider GLP-1 landscape, and how to think about it without either dismissing it or overselling it.

What is compounded semaglutide, in plain terms?

Semaglutide is a glucagon-like peptide-1, or GLP-1, receptor agonist. In the body, GLP-1 is a hormone released from the gut after eating. It slows stomach emptying, influences appetite signalling in the brain, and affects how the pancreas releases insulin. A GLP-1 medication is a synthetic version designed to act on the same receptors for much longer than the natural hormone.

Semaglutide is also the active molecule in several licensed products, each sold under its own brand name and each approved for specific uses. Those approvals came through a formal regulatory process, with the manufacturer demonstrating consistent manufacturing, defined dosing and a body of evidence for the licensed indication. A compounded preparation sits outside that framework. It is made under a different set of rules, by a pharmacy rather than a manufacturer, and it is not interchangeable with an approved product in any regulatory sense.

Compounding itself is a long-established part of pharmacy. It covers everything from a liquid version of a tablet for someone who cannot swallow pills, to the removal of an allergen from a formulation. The licensed medical providers who prescribe compounded medicines do so for individual patients, which is the legal basis for the practice in most jurisdictions. What compounding is not designed to do is supply a population-scale alternative to a licensed product, and regulators have been explicit about that in recent years.

How does compounded semaglutide different from a licensed product?

The clearest difference is the approval process. An approved medicine has been assessed by a regulator for safety, quality and efficacy for a named indication before it reaches the market. A compounded semaglutide product has not been through that assessment. It is prepared under a prescriber's direction, and the responsibility for oversight shifts towards the prescriber, the pharmacy and the patient.

There are practical consequences. Compounded products may be supplied as a lyophilised powder to be reconstituted, or as a ready-to-use liquid, and they may contain an absorption enhancer or other excipients that a licensed product does not. Concentration and dosing can differ from what a patient might expect. Storage requirements can differ too. None of this is automatically unsafe, but it does mean the instructions that come with a licensed pen may not apply to what is in your hands.

It is worth being precise about what is and is not being claimed here. A compounding pharmacy is not permitted to present its output as equivalent to an approved medicine, and no responsible one does. Questions about effectiveness or quality are answered by the pharmacy's own testing and by the prescriber's judgement, not by a regulator's determination. If a supplier implies otherwise, that is a reason to look elsewhere.

Where do compounded tirzepatide and other GLP-1 options fit?

Semaglutide is not the only molecule in this family. Tirzepatide acts on two receptors rather than one, which is why it is often described as a dual GIP GLP-1 agonist: it mimics both glucose-dependent insulinotropic polypeptide and GLP-1. That broader receptor activity is one reason the two are not simply interchangeable in clinical discussion, even though both are prescribed for chronic weight management and for type 2 diabetes in their licensed forms.

Compounded tirzepatide is compounded under the same legal mechanism as compounded semaglutide, and the same cautions apply: no regulatory approval as a compounded product, variable presentation, and a reliance on the prescriber and pharmacy. Anyone comparing the two should be comparing the clinical rationale for one receptor profile over the other, not the marketing language on a website.

For readers who follow the clinical literature, the relevant journals and professional bodies - including the American Diabetes Association and publications in the diabetes, obesity and metabolism field, often abbreviated in citation lists as diabetes obes metab - are the places to look for how these agents are positioned in guidance. That guidance is written about licensed products. It is a starting point for a conversation with a prescriber, not a description of what a compounded preparation will do.

How is it prescribed and dispensed?

The route to a compounded GLP-1 is usually shorter and more digital than the route to a licensed product. A patient typically begins by answering screening questions, and many services ask them to complete an online intake form inside a secure portal. From there, a prescriber reviews your information - history, current medications, relevant blood tests where available - and decides whether treatment is appropriate. If it is, the prescriber issues a prescription and a pharmacy that fills compounded prescriptions prepares and dispatches it.

Legitimate services are transparent about this chain. You should be able to identify who prescribed, which pharmacy dispensed, and how to reach both. You should receive written instructions covering dose escalation, storage and what to do about missed doses. If any of that is vague, treat it as a signal.

What happens after the prescription is written

Once a prescriber approves your medication, the workflow should include a check that the dose and formulation match what was intended, and a clear record of the batch or lot where that is available. Some services also offer periodic review appointments, which matter more with a compounded product than with a licensed one, because tolerance and response can shift as the dose changes.

Payment is a practical consideration that catches people out. Compounded prescriptions are generally not covered by insurance, and they are usually not eligible for reimbursement through an HSA and FSA either, because those accounts are tied to prescribed medicines that meet particular criteria. Confirm the position with your account administrator before assuming a purchase will qualify.

What should you ask before starting treatment?

These are the questions worth putting in writing, whether you are speaking to a clinician or reading a provider's own frequently asked questions page.

• Who is the prescriber, and are they licensed in my jurisdiction? Services that employ board-certified physicians and other licensed medical providers should be able to say so plainly.
• Which pharmacy prepares the product, and is it licensed in my state or country?
• What form does the medication take, and what concentration is it supplied at?
• What is the titration schedule, and who do I contact if I have a bad reaction?
• What monitoring is expected - for example, blood pressure, blood sugar, or periodic blood tests - and who reviews the results?
• What does the service do about supply interruptions, and what is the plan if I need to stop?

The last point deserves emphasis. Stopping the medication abruptly is a common experience, and it is worth knowing in advance what the plan is, because appetite and weight often change when treatment ends. A provider who has no answer to that question has not thought the service through.

Safety, side effects and the limits of what is known

Compounded semaglutide shares the side-effect profile of the drug class. The most commonly reported effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal pain. These are often worst during dose escalation and tend to settle, but they are not trivial, and they are the main reason people stop. More serious problems, including pancreatitis and gallbladder disease, are uncommon but recognised, and anyone with a personal or family history of thyroid cancer or pancreatitis should raise it with a prescriber before starting.

There is a second layer of uncertainty specific to compounded products. Regulators have warned about the risks of unapproved GLP-1 preparations, particularly where the source of the active ingredient is unclear or where dosing instructions are ambiguous. The Food and Drug Administration has taken action against sellers making unsupported claims, and its guidance to consumers is straightforward: check for safety and quality signals, and be sceptical of anything that promises more than a licensed medicine does.

A licensed provider should be willing to discuss all of this without defensiveness. The compounded semaglutide pathway offered by a regulated telehealth service is one example of how the model is meant to work: screening, a prescriber review, a licensed pharmacy, and follow-up. That structure is the minimum. It is not a guarantee of anything beyond it.

Frequently asked questions

Is compounded semaglutide the same as the licensed injection?

No. It contains the same active molecule, but it is not an approved product and it is not interchangeable with one. The formulation, concentration, excipients and delivery device may all differ, and the regulatory oversight is different. Treat the instructions you receive as specific to what you have been given.

How is it administered?

Most commonly as a weekly subcutaneous semaglutide injection, using a syringe and vial or a pre-filled device depending on the pharmacy. Some preparations require reconstitution before use. The dose is escalated gradually over weeks to limit gastrointestinal effects. Follow the written schedule exactly, and do not adjust the dose on your own.

Can I switch between compounded and licensed products?

Only with a prescriber's involvement. Because concentrations and dosing units are not necessarily equivalent, a dose that is correct for one product may be wrong for another. If you are moving in either direction, the change should be managed and documented by the clinician who knows your history.

The short version: compounded semaglutide is a legitimate prescription option in specific circumstances, provided the prescribing and dispensing chain is transparent and the monitoring is real. Ask the questions, keep the answers, and treat any provider who discourages scrutiny as a reason to walk away.

This article is part of an ongoing editorial series. Information current as of publication date.